Table 3 Association between type of irAEs and overall survival.

From: Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients

 

Overall survival (days)

P value

With

Without

Any irAEs

517 (269–923)

242 (96–556)

< 0.001

Endocrine-related irAE

569 (311–1021)

298 (115–597)

< 0.001

 Multiple endocrine-related irAE

817 (557–1825)

296 (114–599)

< 0.001

 Thyroid-related irAE

571 (312–993)

332 (131–653)

< 0.001

 Adrenal-related irAE)

795 (423–1312)

389 (143–757)

< 0.001

 Pituitary-related irAE

956 (452–1458)

389 (145–752)

< 0.001

 Insulin-dependent diabetes

356 (246–1517)

397 (147–780)

0.34

Other irAEs

489 (322–889)

319 (115–740)

< 0.001

 Interstitial pneumonia

532 (274–1030)

376 (134–768)

0.030

 Biliary tract disorders

402 (148–788)

254 (120–543)

0.55

 Enterocolitis

434 (269–1038)

397 (144–767)

0.16

 Skin disorders

561 (390–987)

378 (142–759)

0.023

 Renal tubular disorders

412 (378–612)

397 (146–788)

0.61

 Other irAEs except for above

473 (397–916)

375 (138–768)

0.0097

Endocrine and other irAE complications

515 (391–916)

241 (95–556)

< 0.001

  1. Data are presented as median (IQR). irAEs; immune-related adverse events. Other irAEs except for above included the following irAEs; bone marrow suppression (n=16), peripheral neuropathy (n=15), hepatic disorder (n=11), rhabdomyolysis (n=4), autoimmune pancreatitis (n=2), nephrotic syndrome (n=2), uveitis (n=1) and herpes cornea (n=1). The Mann-Whitney U test was used for analysis.
Back to article page